首页 | 本学科首页   官方微博 | 高级检索  
     


Re-treatment with radium-223: 2-year follow-up from an international,open-label,phase 1/2 study in patients with castration-resistant prostate cancer and bone metastases
Authors:Oliver Sartor MD  Daniel Heinrich MD  Neil Mariados MD  Maria José Méndez Vidal MD  Daniel Keizman MD  Camilla Thellenberg Karlsson MD  Avivit Peer MD  Giuseppe Procopio MD  Stephen J. Frank MD  Kalevi Pulkkanen MD  Eli Rosenbaum MD  Stefano Severi MD  José Trigo MD  Lucia Trandafir MD  Volker Wagner MD  Rui Li MS  Luke T. Nordquist MD
Affiliation:1. Departments of Medicine and Urology, Tulane Cancer Center, New Orleans, Louisiana;2. Department of Oncology, Akershus University Hospital, Lørenskog, Norway;3. Department of Radiation Oncology, Associated Medical Professionals of New York, PLLC, Syracuse, New York;4. Oncology Department, Maimonides Institute of Biomedical Research (IMIBIC), Reina Sofia Hospital, University of Cordoba, Cordoba, Spain;5. Genitourinary Oncology Unit, Meir Medical Center, Kfar-Saba, and Sackler School of Medicine, Tel 6. Aviv University, Tel Aviv, Israel;7. Department of Radiation Sciences, Cancer Center Norrlands University, Umeå, Sweden;8. Division of Oncology, Rambam Health Care Campus, Haifa, Israel;9. Division of Medical Oncology, Fondazione Istituto Nazionale Tumori Oncologia Medica Genitourinaria, Milan, Italy;10. Department of Oncology, Hadassah Hebrew University Medical Center, Jerusalem, Israel;11. Department of Oncology, Kuopio University Hospital, Kuopio, Finland;12. Uro-Oncology Unit, Rabin Medical Center, Davidoff Center, Petah Tikva, Israel;13. Nuclear Medicine Therapeutic Unit, Romagnolo Scientific Institute for the Study and Care of Cancer, IRST IRCCS, Meldola, Italy;14. Department of Medical Oncology, Hospital Universitario Virgen de la Victoria, Málaga, Spain;15. Global Clinical Development, Bayer Pharma AG, Basel, Switzerland;16. Global Research and Development Statistics, Bayer HealthCare Pharmaceuticals, Whippany, New Jersey;17. Department of Medical Oncology, GU Research Network, LLC, Omaha, Nebraska
Abstract:
Keywords:alkaline phosphatase  prostate-specific antigen  safety  SSEs  survival  symptomatic skeletal events
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号